Last update Aug. 22, 2022
Very Low Risk
We do not have alternatives for Peginterferon beta-1a since it is relatively safe.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Peginterferon beta-1a is also known as
Peginterferon beta-1a in other languages or writings:
Peginterferon beta-1a belongs to this group or family:
Main tradenames from several countries containing Peginterferon beta-1a in its composition:
|Molecular weight||> 20.000||daltons|
|VD||6.9 (3.5 - 10.4)||l/Kg|
Write us at email@example.com
e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Peginterferon beta or pegylated interferon beta-1a is a conjugation of interferon beta with a 20,000 dalton methoxy-polyethylene glycol (PEG) molecule, with the aim of increasing the half-life of interferon beta to delay its elimination from the body, in addition to improving certain properties of the drug. It has the same indications as interferon beta (treatment of relapsing Multiple Sclerosis). Subcutaneous administration.
It is excreted in breast milk in an undetectable or clinically insignificant amount. (Houtchens 2022)
Its null oral bioavailability minimizes the passage into plasma of the infant from ingested breast milk; due to its protein nature, it degrades in the gastrointestinal tract and is not absorbed, except in preterm infants and immediate neonatal period (2 first weeks after birth), in which there may be greater intestinal absorption.
No side effects have been observed in nursing infants after maternal treatment for months or years with interferon beta (1a or 1b). (Ciplea 2020, Hellwig 2011, Rockhoff 2012, Hale 2012, Fragoso 2013)
According to the manufacturer, Peginterferon beta-1a can be used during breastfeeding. (EMA 2019)
Several scientific societies consider that interferon beta can probably be used safely during breastfeeding (Hale, LactMed, Thöne 2017, Briggs 2015, Mahadevan 2006, Bove 2014, Bodiguel 2014).
See below the information of these related products: